Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in J Immunother Retrieve available abstracts of 29 articles: HTML format

Single Articles

February 2024
1. BASIR S, Bosiers J, Westgeest HM, Yick DCY, et al
   Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient.
   J Immunother. 2024 Feb 27. doi: 10.1097/CJI.0000000000000509.
   PubMed     Abstract available
   
   
   
2. ARAK H, Erkilic S, Yaslikaya S, Eylemer Mocan E, et al
   The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
   J Immunother. 2024 Feb 7. doi: 10.1097/CJI.0000000000000508.
   PubMed     Abstract available
   
   
   
3. DE JOODE K, Mora AR, van Schaik RHN, Zippelius A, et al
   Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
   J Immunother. 2024 Feb 6. doi: 10.1097/CJI.0000000000000506.
   PubMed     Abstract available
   
   
   September 2023
4. D'ANNIBALLE VM, Huang MN, Lueck BD, Nicholson LT, et al
   Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
   J Immunother. 2023 Sep 20. doi: 10.1097/CJI.0000000000000487.
   PubMed     Abstract available
   
   
   
5. SCHON V, Stocker D, Jungst C, Dummer R, et al
   Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report.
   J Immunother. 2023 Sep 19. doi: 10.1097/CJI.0000000000000486.
   PubMed     Abstract available
   
   
   June 2023
6. BUCHBINDER EI, Pfaff KL, Turner MM, Manos M, et al
   Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
   J Immunother. 2023;46:192-196.
   PubMed     Abstract available
   
   
   May 2023
7. ZHANG L, Cao L, Li S, Wang L, et al
   Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations.
   J Immunother. 2023 May 24. doi: 10.1097/CJI.0000000000000475.
   PubMed     Abstract available
   
   
   April 2023
8. VAN ZEIJL MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, et al
   Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
   J Immunother. 2023 Apr 28. doi: 10.1097/CJI.0000000000000468.
   PubMed     Abstract available
   
   
   February 2023
9. EMONET C, Tetart F, Bauvin O, Cellier L, et al
   Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
   J Immunother. 2023;46:59-63.
   PubMed     Abstract available
   
   
   September 2022
10. KENNEDY OJ, Neary MT
    Brief Communication on the Impact of beta-blockers on Outcomes in Patients Receiving Cancer Immunotherapy.
    J Immunother. 2022;45:303-306.
    PubMed     Abstract available
    
    
    July 2022
11. DE VOS L, Carrillo Cano TM, Zarbl R, Klumper N, et al
    CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
    J Immunother. 2022 Jul 22. pii: 00002371-990000000-00015.
    PubMed     Abstract available
    
    
    May 2022
12. OSWALT CJ, Al-Rohil RN, Theivanthiran B, Haykal T, et al
    Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.
    J Immunother. 2022 May 30. pii: 00002371-990000000-00010.
    PubMed     Abstract available
    
    
    
13. FRANKE V, Stahlie EHA, van der Hiel B, van de Wiel BA, et al
    Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
    J Immunother. 2022 May 18. pii: 00002371-990000000-00009.
    PubMed     Abstract available
    
    
    
14. ZHANG S, Chen K, Zhao Z, Zhang X, et al
    Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM).
    J Immunother. 2022 May 10. pii: 00002371-990000000-00007.
    PubMed     Abstract available
    
    
    December 2021
15. PALA L, Conforti F, Pagan E, Bagnardi V, et al
    Different Response to Immunotherapy According to Melanoma Histologic Subtype.
    J Immunother. 2021 Dec 15. pii: 00002371-900000000-99307.
    PubMed     Abstract available
    
    
    November 2021
16. MONTES G, Duval F, Eldani C, Amico S, et al
    Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.
    J Immunother. 2021;44:348-350.
    PubMed     Abstract available
    
    
    September 2021
17. LI Y, Meng Y, Sun H, Ye L, et al
    The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy.
    J Immunother. 2021 Sep 13. pii: 00002371-900000000-99321.
    PubMed     Abstract available
    
    
    
18. JANSSEN JBE, Leow TYS, Herbschleb KH, Gijtenbeek JMM, et al
    Immune Checkpoint Inhibitor-related Guillain-Barre Syndrome: A Case Series and Review of the Literature.
    J Immunother. 2021;44:276-282.
    PubMed     Abstract available
    
    
    August 2021
19. NAIK GS, Buchbinder EI, Cohen JV, Manos MP, et al
    Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
    J Immunother. 2021 Aug 18. pii: 00002371-900000000-99327.
    PubMed     Abstract available
    
    
    June 2021
20. MARTINEZ-VILA C, Laguna JC, Segui E, Ruiz G, et al
    Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.
    J Immunother. 2021;44:204-207.
    PubMed     Abstract available
    
    
    May 2021
21. ZHANG S, Chen K, Liu H, Jing C, et al
    PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
    J Immunother. 2021 May 24. pii: 00002371-900000000-99339.
    PubMed     Abstract available
    
    
    
22. PERSA OD, Schatton K, Rubben A, Berking C, et al
    Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients.
    J Immunother. 2021 May 24. pii: 00002371-900000000-99338.
    PubMed     Abstract available
    
    
    April 2021
23. KOCH EAT, Nickel FT, Heinzerling L, Schulz YK, et al
    Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy.
    J Immunother. 2021;44:114-117.
    PubMed     Abstract available
    
    
    March 2021
24. COWEY CL, Scherrer E, Boyd M, Aguilar KM, et al
    Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
    J Immunother. 2021 Mar 17. pii: 00002371-900000000-99347.
    PubMed     Abstract available
    
    
    
25. STURMER SH, Lechner A, Berking C
    Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors.
    J Immunother. 2021 Mar 17. pii: 00002371-900000000-99346.
    PubMed     Abstract available
    
    
    February 2021
26. KARTOLO A, Deluce J, Holstead R, Hopman W, et al
    Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma.
    J Immunother. 2021 Feb 5. pii: 00002371-900000000-99350.
    PubMed     Abstract available
    
    
    January 2021
27. SMITHY JW, Pianko MJ, Maher C, Postow MA, et al
    Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
    J Immunother. 2021;44:9-15.
    PubMed     Abstract available
    
    
    December 2020
28. RUINI C, Haas C, Mastnik S, Knott M, et al
    Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
    J Immunother. 2020 Dec 14. doi: 10.1097/CJI.0000000000000354.
    PubMed     Abstract available
    
    
    October 2020
29. FRADLEY MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, et al
    Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma.
    J Immunother. 2020 Oct 9. doi: 10.1097/CJI.0000000000000341.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.